WO2011130429A9 - Methods and materials for treating lung cancer - Google Patents
Methods and materials for treating lung cancer Download PDFInfo
- Publication number
- WO2011130429A9 WO2011130429A9 PCT/US2011/032350 US2011032350W WO2011130429A9 WO 2011130429 A9 WO2011130429 A9 WO 2011130429A9 US 2011032350 W US2011032350 W US 2011032350W WO 2011130429 A9 WO2011130429 A9 WO 2011130429A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- materials
- methods
- lung cancer
- treating lung
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/30—Copper compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32373710P | 2010-04-13 | 2010-04-13 | |
| US61/323,737 | 2010-04-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2011130429A2 WO2011130429A2 (en) | 2011-10-20 |
| WO2011130429A9 true WO2011130429A9 (en) | 2012-02-23 |
Family
ID=44799300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2011/032350 Ceased WO2011130429A2 (en) | 2010-04-13 | 2011-04-13 | Methods and materials for treating lung cancer |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2011130429A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8835506B2 (en) | 2008-06-05 | 2014-09-16 | Stc.Unm | Methods and related compositions for the treatment of cancer |
| EP3052655B1 (en) * | 2013-09-30 | 2018-11-07 | Institute For Cancer Research D/b/a The Research Institute of Fox Chase Cancer Center | Closantel in combination with temozolomide for use in the treatment of a cancer in which is thymine dna glycosylase expressed |
-
2011
- 2011-04-13 WO PCT/US2011/032350 patent/WO2011130429A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011130429A2 (en) | 2011-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2542585B8 (en) | Methods for treating colorectal cancer | |
| EP2655309A4 (en) | Methods and compositions for treating lung cancer | |
| EP2542584B8 (en) | Methods for treating pancreatic cancer | |
| EP2649391B8 (en) | Drying apparatus and methods | |
| EP2549963A4 (en) | Systems and methods for prostate treatment | |
| WO2011140517A9 (en) | Methods for treating diseases of the lung | |
| WO2012009611A9 (en) | Methods and compositions for cancer immunotherapy | |
| IL223295A0 (en) | Lung cancer biomarkers and uses thereof | |
| IL231426A (en) | Lung cancer biomarkers and uses thereof | |
| SG10201500124VA (en) | Methods and Compositions for Treating Cancer | |
| EP2564200B8 (en) | Cancer biomarkers and methods of use thereof | |
| WO2012061413A3 (en) | Isoflavonoid compositions and methods for the treatment of cancer | |
| WO2012018877A9 (en) | Treating breast cancer with anti-il-19 antibody | |
| EP2590712A4 (en) | System and method for hyperthermic tumor treatment | |
| WO2012030896A9 (en) | Methods for treatment of non-small cell lung cancer | |
| EP2593111A4 (en) | New compounds for treating cancer and other diseases | |
| WO2011130429A9 (en) | Methods and materials for treating lung cancer | |
| EP2537031A4 (en) | Compositions and methods for treating cancer | |
| WO2012061820A9 (en) | Materials and methods for treating radiation poisoning | |
| AU2016202538A1 (en) | Reagents and methods for treating cancer | |
| HK1255654A (en) | Compositions and methods for treating myelofibrosis | |
| HK1189268A (en) | Methods of treating cancer | |
| HK1189267A (en) | Methods of treating cancer | |
| HK1191599A (en) | Compositions and methods for treating cancer | |
| AU2011211693B2 (en) | Pharmaceutical composition for treating and/or preventing cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11769538 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11769538 Country of ref document: EP Kind code of ref document: A2 |